替吉奥联合三维适形放疗治疗局部晚期直肠癌的疗效观察

Clinical study of concurrent chemoradiation with S1 capsule in the treatment of locally advanced rectal cancer

目的观察替吉奥联合三维适形放疗治疗局部晚期直肠癌的疗效及安全性。方法对60例具有可测量指标的局部晚期直肠癌患者给予三维适形放疗,同步口服化疗,其中口服替吉奥组30例,采用替吉奥胶囊80 mg/(m2.d),口服,2次/d,连续服用2周,休息1周,为1个周期;口服希罗达组30例,希罗达2000 mg/(m2.d),口服,2次/d,连续服用2周,休息1周,为1个周期。每例患者至少进行2个周期的治疗,结束后进行评价。结果替吉奥组和希罗达组有效率(CR+PR)分别为86.7%和89.7%,差异无统计学意义(P>0.05),而替吉奥组手足综合征的发生率明显低于希罗达组(P<0.01),胃肠道反应、白细胞下降、放射性直肠炎等不良反应未见明显差异。结论替吉奥联合三维适形放疗治疗局部晚期直肠癌安全有效,值得临床推广应用。

Objective To evaluate the efficacy and toxicity of concurrent chemoradiation with S1 capsule in the treatment of locally advanced rectal cancer.Methods A total of 60 patients with locally advanced rectal cancer were treated with concurrent chemoradiation with S1 capsule or capecitabine.All patients received 2 cycles of chemotherapy at least.Efficacy and toxicities were evaluated according to the RECIST 1.1 standard.Results The total response rate of the S-1 group and capecitabline group were 86.7% and 89.7%,respectively（P0.05）.The hand foot syndrome rate of the S-1 group was lower than that of the capecitabline group.As for the gastrointestinal reaction,leukopenia and radiation proctitis,there was no statistic significance between the two groups.Conclusions Concurrent chemoradiation with S1 capsule is effective and tolerable in the treatment of locally advanced rectal Cancer.